Cannabinol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cannabinol
DrugBank Accession Number
DB14737
Background

Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 310.437
Monoisotopic: 310.193280077
Chemical Formula
C21H26O2
Synonyms
  • 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol
  • Cannabinol
  • Cannabinolo
  • Cannabinolum
  • CBN

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Cannabinol is combined with 1,2-Benzodiazepine.
AcebutololThe risk or severity of Tachycardia can be increased when Cannabinol is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Cannabinol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Cannabinol is combined with Acetophenazine.
AclidiniumThe risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Cannabinol.
AgomelatineThe risk or severity of adverse effects can be increased when Cannabinol is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Cannabinol is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Cannabinol is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Cannabinol is combined with Almotriptan.
AlosetronThe risk or severity of adverse effects can be increased when Cannabinol is combined with Alosetron.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7UYP6MC9GH
CAS number
521-35-7
InChI Key
VBGLYOIFKLUMQG-UHFFFAOYSA-N
InChI
InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3
IUPAC Name
6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol
SMILES
CCCCCC1=CC2=C(C(O)=C1)C1=C(C=CC(C)=C1)C(C)(C)O2

References

General References
Not Available
KEGG Compound
C07580
ChemSpider
2447
BindingDB
50061117
RxNav
1976
ChEBI
3360
ChEMBL
CHEMBL74415
ZINC
ZINC000001530833
Wikipedia
Cannabinol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingTreatmentEpidermolysis Bullosa Dystrophica / Epidermolysis Bullosa Simplex / Epidermolysis Bullosa, Junctional / Kindler Syndrome1
2, 3Not Yet RecruitingTreatmentArthroplasties, Replacement, Knee1
Not AvailableCompletedDiagnosticMarijuana Dependence1
Not AvailableTerminatedTreatmentNausea / Vomiting1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000339 mg/mLALOGPS
logP6.58ALOGPS
logP6.41ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)9.32ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.46 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.74 m3·mol-1ChemAxon
Polarizability37.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on February 01, 2019 22:20 / Updated on February 21, 2021 18:54